national stem-cell therapy logo

Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy

Immunis logo

IRVINE, Calif., Aug. 9, 2022 /PRNewswire/ —¬†Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: www.clinicaltrials.gov/ct2/show/NCT05211986 The open label […]